The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Engineering

Epidemiology

Medicine

Internal Medicine

Emergency Medicine

Show all topics

DOI

10.1016/s0140-6736(12)60768-5

Other Formats

PDF